【CGTN】20th CPC National Congress: Interview with Sinopharm chairman on modernization, innovation and international cooperation
发布时间:2022-10-19

CGTN's Gao Ang talked to Liu Jingzhen, Chairman of the Sinopharm Group and asked him what he understands by the term "Chinese modernization."

LIU JINGZHEN Chairman Sinopharm Group "Chinese modernization is based on national conditions. It's socialist modernization pursued under the leadership of the CPC. Chinese modernization is the modernization of a huge population, of common prosperity for all, of material and cultural-ethical advancement, of harmony between humanity and nature and of peaceful development. Sinopharm Group is the only centrally-administered enterprise that focuses on life, medicine and health. We resolutely implement Xi Jinping's concept of putting people and their lives first. Our enterprise's purpose is to protect life and care for health, which is highly consistent with that. We will also resolutely implement requirements with practical actions."

GAO ANG CGTN Reporter "Tell us about Sinopharm Group's plans for using innovation and scientific research during the 14th Five-Year Plan (2021-25) period."

LIU JINGZHEN Chairman Sinopharm Group "First, for Sinopharm Group, we must take self-reliance, self-improvement, and innovation in science and technology as the primary task. As a company providing products and services, we must achieve high-quality development with practical actions. During the past two years of the pandemic, we have invested 15 billion yuan in scientific and technological research and development. We have also invested more than 30 billion yuan to build three P3 high-level biosafety laboratories and six P3 high-level biosafety production workshops. At present, our annual production capacity of vaccine can reach 10 billion doses. The second is to build sound and complete industrial, supply and value chains that are independent and controllable. Third, we must build a sustainable, coordinated and safe entire industrial layout. We must optimize it and firmly grasp the sustainable, coordinated and safer industrial layout in various fields of life, medicine and health, so as to ensure healthy and sustainable development."

GAO ANG CGTN Reporter "How does Sinopharm Group contribute to the global fight against COVID-19 and help achieve the goal of building a community with a shared future for mankind?"

LIU JINGZHEN Chairman Sinopharm Group "Our vaccine has now been approved in 119 countries around the world. Among them, the heads of state and government of more than 50 countries have received Sinopharm vaccines, which have won wide acclaim. Because medicines and vaccine in all countries are strictly regulated, it is very difficult for our vaccine to enter other countries. But during this pandemic, we have negotiated more than 600 times to promote our vaccine clinical trials in different countries. We are gradually opening up the international market, and have won recognition from the international community. For example, 11 vaccines are currently undergoing clinical trials in the UAE, which was unimaginable in the past, so now we have achieved a breakthrough."

地址:北京市海淀区知春路20号 中国医药大厦

邮编:100191

电话:86-10-82287727

传真:86-10-62033332

版权所有:币游国际

京公网安备 11040102700104号

京ICP备:14023670号-1
【CGTN】20th CPC National Congress: Interview with Sinopharm chairman on modernization, innovation and international cooperation
发布时间:2022-10-19

CGTN's Gao Ang talked to Liu Jingzhen, Chairman of the Sinopharm Group and asked him what he understands by the term "Chinese modernization."

LIU JINGZHEN Chairman Sinopharm Group "Chinese modernization is based on national conditions. It's socialist modernization pursued under the leadership of the CPC. Chinese modernization is the modernization of a huge population, of common prosperity for all, of material and cultural-ethical advancement, of harmony between humanity and nature and of peaceful development. Sinopharm Group is the only centrally-administered enterprise that focuses on life, medicine and health. We resolutely implement Xi Jinping's concept of putting people and their lives first. Our enterprise's purpose is to protect life and care for health, which is highly consistent with that. We will also resolutely implement requirements with practical actions."

GAO ANG CGTN Reporter "Tell us about Sinopharm Group's plans for using innovation and scientific research during the 14th Five-Year Plan (2021-25) period."

LIU JINGZHEN Chairman Sinopharm Group "First, for Sinopharm Group, we must take self-reliance, self-improvement, and innovation in science and technology as the primary task. As a company providing products and services, we must achieve high-quality development with practical actions. During the past two years of the pandemic, we have invested 15 billion yuan in scientific and technological research and development. We have also invested more than 30 billion yuan to build three P3 high-level biosafety laboratories and six P3 high-level biosafety production workshops. At present, our annual production capacity of vaccine can reach 10 billion doses. The second is to build sound and complete industrial, supply and value chains that are independent and controllable. Third, we must build a sustainable, coordinated and safe entire industrial layout. We must optimize it and firmly grasp the sustainable, coordinated and safer industrial layout in various fields of life, medicine and health, so as to ensure healthy and sustainable development."

GAO ANG CGTN Reporter "How does Sinopharm Group contribute to the global fight against COVID-19 and help achieve the goal of building a community with a shared future for mankind?"

LIU JINGZHEN Chairman Sinopharm Group "Our vaccine has now been approved in 119 countries around the world. Among them, the heads of state and government of more than 50 countries have received Sinopharm vaccines, which have won wide acclaim. Because medicines and vaccine in all countries are strictly regulated, it is very difficult for our vaccine to enter other countries. But during this pandemic, we have negotiated more than 600 times to promote our vaccine clinical trials in different countries. We are gradually opening up the international market, and have won recognition from the international community. For example, 11 vaccines are currently undergoing clinical trials in the UAE, which was unimaginable in the past, so now we have achieved a breakthrough."

地址:北京市海淀区知春路20号 中国医药大厦

邮编:100191 电话:86-10-82287727

传真:86-10-62033332

版权所有:币游国际

公安备案号:11040102700104号


京ICP备:14023670号-1